Although ART coverage is increasing in sub-Saharan Africa, several recent studies have noted the persistence of advanced disease (AD), defined as CD4 <200 cells/mm3 or World Health Organization (WHO) Stage III or IV for adults, adolescents and children >5, among patients initiating ART [3–5]. This evidence concerns the gene CD4 and Alzheimer disease.